---
title: "Cabaletta Bio, Inc. (CABA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CABA.US.md"
symbol: "CABA.US"
name: "Cabaletta Bio, Inc."
industry: "Biotechnology"
datetime: "2026-04-14T22:03:29.932Z"
locales:
  - [en](https://longbridge.com/en/quote/CABA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CABA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CABA.US.md)
---

# Cabaletta Bio, Inc. (CABA.US)

## Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.cabalettabio.com](https://www.cabalettabio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.12 | 265 | - | - | - |
| PB | 3.18 | 253 | 1.77 | 1.27 | 0.79 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-02T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 67% |
| Overweight | 1 | 11% |
| Hold | 2 | 22% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.26 |
| Highest Target | 30.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CABA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CABA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CABA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CABA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**